Skip to main content

Mylan (MYL) - Get Viatris, Inc. Report is facing a battle over its board members from shareholders who are leery of the compensation the company's executives have received in the midst of backlash over the pricing of the company's EpiPen treatment. 

Big pension funds are looking to block the election of a number of board members, including chairman and former CEO Robert Coury who received $100 million in compensation last year. 

The New York City and New York State comptrollers, California State Teachers' Retirement System and Dutch pension fund PGGM all signed a letter sent to shareholders urging them not to reward the company's leadership for a "costly record of compensation, risk and compliance failures."

TheStreet Recommends

Stocks have rebounded following a sharp sell off last week. Jim Cramer believes the rebound is real and gives investors advice on how to play the market going forward